Related Experiment Video
Updated: May 21, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables
Vincenzo Maria Altieri1, Roberto Castellucci, Pietro Palumbo
1Department of Urology, Chair and School of Urology, University of Chieti, Chieti, Italy. vmaltieri @ alice.it
Urologia Internationalis
|June 23, 2012
Summary
This study found that recurrence and progression rates in non-muscle-invasive bladder cancer (NMIBC) align with European Organization for Research and Treatment of Cancer (EORTC) risk tables, with a slight decrease in recurrence for intermediate- and high-risk patients.
Area of Science:
- Urology
- Oncology
- Cancer Research
Background:
- Non-muscle-invasive bladder cancer (NMIBC) requires accurate prognostication for effective management.
- Transurethral resection of bladder cancer (TURBT) followed by adjuvant intravesical therapy is a standard treatment approach.
- The European Organization for Research and Treatment of Cancer (EORTC) provides risk stratification tools for NMIBC.
Purpose of the Study:
- To evaluate recurrence and progression rates of NMIBC at 1, 3, and 5 years post-TURBT.
- To compare observed outcomes with predictions from the EORTC risk tables.
- To assess the utility of EORTC risk stratification in clinical practice for NMIBC management.
Main Methods:
- A cohort of 259 NMIBC patients treated with TURBT between 2002 and 2011 was analyzed.
- Patients were categorized into four groups based on EORTC risk score criteria.
- Recurrence and progression probabilities were calculated for each risk group.
Main Results:
- Observed recurrence and progression rates in the patient cohort were comparable to EORTC risk score predictions.
- A statistically significant reduction in recurrence rates was noted in the intermediate- and high-risk patient groups.
- The findings support the applicability of EORTC risk tables for NMIBC prognostication.
Conclusions:
- The EORTC risk tables are valuable tools for predicting recurrence and progression in NMIBC.
- Integration of EORTC risk stratification into clinical practice is recommended for NMIBC management.
- Adjuvant intravesical therapies may contribute to improved recurrence rates in higher-risk NMIBC patients.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...